Statins tied to lower mortality in some NSCLC subtypes

  • Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statin use before and after lung cancer diagnosis was associated with significantly lower mortality for patients with squamous cell carcinoma (SCC) and adenocarcinoma, but not small cell lung cancer (SCLC).

Why this matters

  • Prior studies have not adequately emphasized the effects of statins on all lung cancer subtypes.

Study design

  • 19,974 patients with lung cancer from the Surveillance, Epidemiology, and End Results-Medicare database.
  • Funding: American Cancer Society; others.

Key results

  • Statin use at baseline was associated with significantly lower mortality in patients with SCC (HR, 0.89; 95% CI, 0.82-0.96) and adenocarcinoma (HR, 0.87; 95% CI, 0.82-0.94), but not with SCLC (HR, 1.05; 95% CI, 0.92-1.20).
  • Postdiagnostic long-term statin use was associated with significantly lower mortality in patients with SCC (HR, 0.68; 95% CI, 0.59-0.79) and adenocarcinoma (HR, 0.78; 95% CI, 0.68-0.89), but not SCLC (HR, 1.16; 95% CI, 0.93-1.43).
  • Atorvastatin and simvastatin were associated with lower mortality in SCC and adenocarcinoma at baseline and postdiagnosis.
  • Association of statin use and decreased mortality was only found in early-stage disease.
  • No statin was significantly associated with decreased mortality in SCLC, although there was a trend toward an increased mortality risk with long-term pravastatin use (HR, 1.8; 95% CI, 1.00-3.51).

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit